Indivior Pharmaceuticals (INDV) Short term Debt (2021 - 2025)

Indivior Pharmaceuticals' Short term Debt history runs 5 years deep, the most recent figure standing at $29.0 million for Q4 2025.

• In Q4 2025, Short term Debt rose 61.11% year-over-year to $29.0 million; the TTM figure through Dec 2025 stood at $29.0 million (up 61.11% YoY), while the FY2025 annual figure was $29.0 million, up 61.11% from the prior year.
• Short term Debt was $29.0 million for Q4 2025 at Indivior Pharmaceuticals, up from $18.0 million in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $29.0 million in Q4 2025 to a low of $3.0 million in Q4 2021.
• Historically, Short term Debt has averaged $13.8 million across 5 years, with a median of $18.0 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Short term Debt changed 0.0% in 2022, then soared 500.0% in 2024.
• A 5-year view of Short term Debt shows it stood at $3.0 million in 2021, then changed by 0.0% to $3.0 million in 2022, then changed by 0.0% to $3.0 million in 2023, then jumped by 500.0% to $18.0 million in 2024, then soared by 61.11% to $29.0 million in 2025.
• The last three Short term Debt figures came in at $29.0 million (Q4 2025), $18.0 million (Q3 2025), and $18.0 million (Q2 2025), per Business Quant data.